Showing 121 - 140 results of 1,040 for search '(( significant decrease cgas ) OR ( significant ((teer decrease) OR (greatest decrease)) ))', query time: 4.02s Refine Results
  1. 121
  2. 122
  3. 123

    Alpha test. by Yuanquan Lu (17125093)

    Published 2023
    Subjects:
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128

    Alpha test. by Yuanquan Lu (17125093)

    Published 2023
    Subjects:
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134

    Image_2_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.tif by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”
  15. 135

    Table_7_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.pdf by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”
  16. 136

    Table_2_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.pdf by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”
  17. 137

    Table_8_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.pdf by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”
  18. 138

    Image_1_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.tif by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”
  19. 139

    Image_4_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.tif by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”
  20. 140

    Image_5_Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.tif by Joseph R. Podojil (12050717)

    Published 2022
    “…The present studies describe a novel use for ONP-302, employing an altered dosing scheme to reprogram myeloid cells resulting in significant enhancement of tumor immunity. ONP-302 infusion decreased tumor growth via the activation of the cGAS/STING pathway within myeloid cells, and subsequently increased NK cell activation via an IL-15-dependent mechanism. …”